Foreword

Journal of Clinical Virology

Volumn 46, Issue SUPPL. 2, 2009, Pages

  Singhasivanon, Pratap ^a   Jacobson, Julie ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Cohort study; Dengue disease dynamics; Plaque reduction neutralisation test

Indexed keywords

DENGUE VACCINE;

ABSENTEEISM; ARTICLE; DENGUE; DISEASE SEVERITY; DISEASE SURVEILLANCE; ENDEMIC DISEASE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; SERODIAGNOSIS; SEROTYPE; THAILAND; WORLD HEALTH ORGANIZATION;

EID: 70349439123     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(09)70285-9     Document Type: Article

References (13)

1. Halstead S.B. Dengue. Lancet 370 (2007) 1644-1652
2. Guy B., Nougarede N., Begue S., et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 26 (2008) 5712-5721
3. Anez G., Balza R., Valero N., and Larreal Y. [Economic impact of dengue and dengue hemorrhagic fever in the State of Zulia, Venezuela, 1997-2003]. Rev Panam Salud Publica 19 (2006) 314-320
4. Clark D.V., Mammen Jr. M.P., Nisalak A., et al. Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels. Am J Trop Med Hyg 72 (2005) 786-791
5. Okanurak K., Sornmani S., and Indaratna K. The cost of dengue hemorrhagic fever in Thailand. Southeast Asian J Trop Med Public Health 28 (1997) 711-717
6. Whitehead S.S., Blaney J.E., Durbin A.P., and Murphy B.R. Prospects for a dengue virus vaccine. Nat Rev Microbiol 5 (2007) 518-528
7. Guy B., and Almond J.W. Towards a dengue vaccine: progress to date and remaining challenges. Comp Immunol Microbiol Infect Dis 31 (2008) 239-252
8. Russell P.K., Nisalak A., Sukhavachana P., and Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 99 (1967) 285-290
9. Edelman R., and Hombach J. Guidelines for the clinical evaluation of dengue vaccines in endemic areas: summary of a World Health Organization Technical Consultation. Vaccine 26 (2008) 4113-4119
10. Sabcharoen A. Dengue clinical trial development: from WHO guidelines to field evaluation. Presentation at the Dengue Vaccine II Symposium. Second International Conference on Dengue and Dengue Haemorrhagic Fever. Phuket Thailand, 15-17 October 2008.
11. Guirakhoo F., Arroyo J., Pugachev K.V., et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 75 (2001) 7290-7304
12. Guirakhoo F., Kitchener S., Morrison D., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2 (2006) 60-67
13. Kuritsky J. The economic and non-economic burden of dengue. Presentation at the Dengue Vaccine II Symposium. Second International Conference on Dengue and Dengue Haemorrhagic Fever. Phuket Thailand, 15-17 October 2008.